The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| License and collaboration revenue | 139,743 |
| Research and development expense-External Research And Development Expenses | 142,695 |
| Research and development expense-Employee Related Expenses | 117,366 |
| General and administrative expenses-External General And Administrative Expenses | 28,319 |
| General and administrative expenses-Employee Related Expenses | 43,124 |
| Facility and information technology related expenses | 59,093 |
| Depreciation and amortization | 22,294 |
| Stock-based compensation | 94,244 |
| Interest and other income | 43,733 |
| Other segment items | -243,667 |
| Net loss | -79,992 |
| Depreciation and amortization | 22,294 |
| Amortization of investment discount (premiums) | 15,958 |
| In-process research and development charge | 14,507 |
| Stock-based compensation expense | 94,244 |
| Change in operating lease right-of-use assets | 10,388 |
| Change in fair value of derivative liabilities | 700 |
| Change in fair value of contingent consideration liabilities | -180 |
| Change in fair value of non-controlling equity investments | 3,942 |
| Realized loss (gain) on sale of marketable securities | -399 |
| Gain on sale of equity method investment | 255,146 |
| Prepaid expenses and other current assets | -4,511 |
| Accounts payable | 6,040 |
| Accrued expenses and other liabilities | 7,685 |
| Operating lease liabilities | -13,505 |
| Deferred revenue | -135,417 |
| Other long-term liabilities | -330 |
| Net cash provided by (used in) operating activities | -345,102 |
| Purchases of property and equipment | 14,946 |
| Purchases of marketable securities | 1,209,792 |
| Maturities of marketable securities | 842,489 |
| Proceeds from sale of marketable securities | 5,743 |
| Cash paid for acquisition, net | 78 |
| Proceeds from sale of equity method investment | 255,146 |
| Net cash provided by (used in) investing activities | -121,438 |
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | 470,513 |
| Proceeds from issuances of stock under espp | 2,764 |
| Equipment financings, net | 0 |
| Proceeds from exercise of stock options | 4,772 |
| Proceeds from private stock issuance | 0 |
| Net cash provided by (used in) financing activities | 478,049 |
| Net change in cash, cash equivalents and restricted cash | 11,509 |
| Cash, cash equivalents and restricted cash-beginning of year | 290,111 |
| Cash, cash equivalents and restricted cash-end of year | 301,620 |
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)